Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide
Neuro-Oncology · 10.02.2025 · 27 (2) · 557-566
DOI: 10.1093/neuonc/noae205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 01.10.2024. Verfasst von Thomas Zeyen und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Neoplasm, Residual, Chemoradiotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: German Ministry for Education and Research.
Abstract (Originalsprache)
Background
Maximum tumor resection improves overall survival (OS) in patients with glioblastoma. The extent of resection (EOR) is historically dichotomized. The response assessment in neuro-oncology (RANO) resects group recently proposed criteria for volumetry-based EOR assessment in patients that were treated according to Stupp´s protocol. The purpose of this study was (1) to investigate the prognostic value of EOR in patients receiving combined chemotherapy with lomustine (CCNU)/temozolomide (TMZ), and (2) to analyze the prognostic performance of binary EOR assessment compared to volumetric assessment.
Methods
Seventy-eight patients with newly diagnosed MGMT-methylated GBM undergoing tumor resection followed by radiochemotherapy with CCNU/TMZ were included in this study. Residual contrast-enhancing (CE) tumor volume after the first resection was measured and its influence on OS and progression-free survival was analyzed using uni- and multivariable Cox regression analysis as well as two-sided log-rank test. Patients were divided into residual tumor volume (RTV) ≤1 cm³, >1–≤5 cm³, and >5 cm³ following the proposed criteria of the RANO resect group.
Results
Prolonged OS was associated with age <60 years, low RTV, and gross total resection. RTV had a superior prognostic value compared to binary EOR assessment. Patients with total or near total resection of CE tumor (≤ 1 cm³ RTV) showed prolonged OS (median 54.4 months, 95% CI: 46.94–not reached), with a 5-year survival rate of 49%.
Conclusions
Low RTV is associated with increased survival in glioblastoma patients undergoing radiochemotherapy with CCNU/TMZ. This study demonstrates the applicability of the recently proposed RANO resect criteria in this subgroup of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany.
- Center for Integrated Oncology (CIO ABCD), University Hospital Bonn, Bonn, Germany.
- Department of Neuroradiology, University Hospital Bonn, Bonn, Germany.
- Department of Vascular Neurology, Center for Neurology, University Hospital Bonn, Bonn, Germany.
- Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
- Dr. Senckenberg Institute of Neurooncology, University of Frankfurt, Frankfurt, Germany.
ORCID-Profile: Thomas Zeyen, Matthias Schneider, Ghazaleh Tabatabai, Norbert Galldiks, Walter Stummer, Martin Glas
Förderung
- German Ministry for Education and Research
Zitieren
APA
Zeyen, T., Böhm, L., Paech, D., Schäfer, N., Tzaridis, T., Duffy, C., Nitsch, L., Schneider, M., Potthoff, A. L., Schneider-Rothhaar, J. L., Steinbach, J. P., Hau, P., Kowalski, T., Seidel, C., Krex, D., Grauer, O., Goldbrunner, R., Zeiner, P. S., Tabatabai, G., …, & Schaub, C. (2025). Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide. Neuro-Oncology, 27(2), 557-566. https://doi.org/10.1093/neuonc/noae205
Vancouver
Zeyen T, Böhm L, Paech D, Schäfer N, Tzaridis T, Duffy C, et al. Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide. Neuro-Oncology. 2025;27(2):557-566. doi:10.1093/neuonc/noae205
BibTeX
@article{Zeyen2025,
author = {Zeyen, Thomas and Böhm, Laura and Paech, Daniel and Schäfer, Niklas and Tzaridis, Theophilos and Duffy, Cathrina and Nitsch, Louisa and Schneider, Matthias and Potthoff, Anna-Laura and Schneider-Rothhaar, Javen Lennard and Steinbach, Joachim Peter and Hau, Peter and Kowalski, Thomas and Seidel, Clemens and Krex, Dietmar and Grauer, Oliver and Goldbrunner, Roland and Zeiner, Pia Susan and Tabatabai, Ghazaleh and Galldiks, Norbert and Stummer, Walter and Hattingen, Elke and Glas, Martin and Gkika, Eleni and Vatter, Hartmut and Radbruch, Alexander and Herrlinger, Ulrich and Weller, Johannes and Schaub, Christina},
title = {Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {2},
pages = {557--566},
doi = {10.1093/neuonc/noae205}
}
EUVIMED